A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

Prior treatment

• Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
• Active inflammatory bowel disease within 28 days prior to first dose
• Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
• Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
• Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
• Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
• Local radiotherapy or 4. Bone marrow irradiation \> 30% for bone metastasis before the first medication
• Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
• Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
• Previous history of severe allergy of unknown origin
• According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons

Other illness

• Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
• Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
• Participants with any severe and/or uncontrolled disease
• Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
• Failure to control serous effusions requiring repeated drainage
• History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;

Other

• Had wounds or fractures that had not been healed for a long time
• Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
• Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain

• Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
• Age: 18-75 years (including the boundary when signing the informed consent form)
• Eastern Cooperative Oncology Group (ECOG) score: 0-1
• Expected survival of more than 3 months
• Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
• HER2-Abnormally Expressed tested
• Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
• Participants should agree to use contraception during the study and for 6 months after the end